Miravista Diagnostics LLC

Miravista Diagnostics LLC, an Indianapolis-based clinical laboratory, delivers reference laboratory fungal and microbiology diagnostic testing services to the Department of Veterans Affairs and the National Institutes of Health as a prime contractor competing full-and-open, without set-asides, on the strength of proprietary patent-protected fungal testing methodologies that justify sole-source procurements.

Miravista operates as a for-profit limited liability company and manufacturer of goods with headquarters at 4705 Decatur Boulevard, Indianapolis, Indiana. The vendor competes exclusively as a prime under full-and-open procurements with no set-aside designations. NAICS concentration is dominated by Medical Laboratories (68 awards), with secondary activity in Testing Laboratories and Services (7 awards) and Research and Development in Biotechnology (3 awards). The vendor's PSC footprint is predominantly Reference Laboratory Testing (80 awards).

Customer concentration is heavily concentrated within the Department of Veterans Affairs. VISN 10 accounts for 38 awards valued at $3.7 million combined potential value, followed by VISN 9 (7 awards, $1.5 million) and VISN 16 (12 awards, $577 thousand)—together representing 72% of recent awards and 97% of combined potential value across all eleven customer agencies. Secondary customers include the NIH Clinical Center (5 awards, $314 thousand), the CDC (5 awards, $102 thousand), and the National Institute of Allergy and Infectious Diseases (NIAID) as a grant funder. The gap between award count and dollar concentration reflects the VA's pattern of issuing numerous task orders, many in the $15,000–$200,000 range, under multiple service-network-specific indefinite delivery contracts.

Miravista holds five active IDCs with the VA. The largest ceiling values are the VISN 10 contract awarded August 5, 2026, for indy fungal testing services ($653 thousand, through July 31, 2031) and the VISN 10 contract awarded November 25, 2025, for specialized fungal laboratory testing ($304 thousand, through November 24, 2030). The VISN 9 IDC, awarded May 20, 2025, carries a $462 thousand ceiling through May 19, 2030, with performance in Nashville, Tennessee. Additional parent vehicles include a VISN 10 contract valued at $238 thousand (ultimate completion November 1, 2026) and a VISN 10 contract valued at $240 thousand (ultimate completion November 24, 2025). Recent delivery-order activity under these IDCs ranges from $15,877 to $199,677 per order, with 20 orders issued across the five named IDCs.

Representative prime awards include a $123,074 delivery order from VISN 10 issued August 5, 2026, for indy fungal testing services (ultimate completion July 31, 2027, performed in Indianapolis), a $462,375 delivery order from VISN 9 issued May 20, 2025, for reference laboratory fungal testing services (through May 19, 2030, performed in Nashville), and a $43,000 purchase order from the NIH Clinical Center issued March 22, 2022, for fungal testing services (completion March 21, 2025). Miravista is also a recipient of federal grant funding from NIAID for development of a Coccidioides cytokine release assay, awarded August 1, 2023, with performance through July 31, 2027, focused on diagnostic tool innovation for endemic mycosis.

Activity has declined moderately from a peak of seven awards in 2025 to four in 2026 year-to-date. Four awards (combined potential value $197 thousand) face ultimate completion within the next twenty-four months and are therefore subject to recompete. The vendor operates wholly as a prime contractor with zero subcontract activity across the recent award portfolio. Combined obligated dollars ($9.2 million) exceed combined potential-value ceilings ($6.4 million), suggesting the VA has exercised most option periods and released funding beyond initial ceiling estimates on renewal contracts.